GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (NAS:DCTH) » Definitions » Long-Term Capital Lease Obligation

Delcath Systems (Delcath Systems) Long-Term Capital Lease Obligation

: $0.00 Mil (As of Dec. 2023) 中文

View and export this data going back to 2000. Start your Free Trial

Delcath Systems's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Delcath Systems's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($0.21 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).


Delcath Systems Long-Term Capital Lease Obligation Historical Data

The historical data trend for Delcath Systems's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.45 0.21 - -

Delcath Systems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Delcath Systems  (NAS:DCTH) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Delcath Systems Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (Delcath Systems) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Executives
Vojo Vukovic officer: See Remarks C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Gerard J Michel director, officer: Chief Executive Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Sandra Pennell officer: See Remarks C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
David L. Hoffman officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
John Purpura officer: EVP, Regulatory Affairs 600 FIFTH AVENUE, 23RD FLOOR, NEW YORK NY 10020
John Richard Sylvester director C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Salamon Steven A J director 25 ADMIRAL ROAD, TORONTO A6 M5R 2L4
Rosalind Advisors, Inc. director, other: See Remarks 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Kevin Muir officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Anthony Dias officer: Vice President of Finance C/O SEACHANGE INTERNATIONAL, 50 NAGOG PARK, ACTON MA 01720
Gil Aharon director 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Johnny John officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Christine Padula officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203